Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials

Review (26 RCTs; n=10 821) found“treat & extend regimen“most effective for improvement in Best Corrected Visual Acuity (BCVA) (letters, SMD=21.41; 95% CI 19.86- 22.95) and >3 lines of BCVA improvement (OR=2.83;1.27-4.38) but did not reduce retreatment times vs monthly injection.

BMJ Open